GU Cancers 2022 | BLC2001: erdafitinib for the treatment of metastatic urothelial carcinoma

Yohann Loriot, MD, PhD, Gustave Roussy, Villejuif, France, and University of Paris-Saclay, Gif-sur-Yvette, France, talks on the pan-FGFR inhibitor, erdafitinib, which had previously demonstrated activity in patients with metastatic urothelial cancer (mUC) who harbor FGFR mutations in the primary analysis at 11 months of the Phase II BLC2001 (NCT02365597) clinical trial. There has now been a follow-up of the more than 2 years, the results of which were presented at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers (GU) Symposium 2022. An overall response rate (ORR) of 40% and a safety profile consistent with the primary analysis was shown, with erdafitnib therefore demonstrating consistent activity and a manageable safety profile in patients with mUC harboring FGFR alterations. This interview took place at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2022 in San Francisco, CA.